PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Paediatrician Publishers, LLC 2012-08-01
Sarja:Pediatričeskaâ Farmakologiâ
Aiheet:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Linkit:https://www.pedpharma.ru/jour/article/view/302
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia